Year: 2016

A Cross-Sectional Analysis of Economic, Medical, and Legal Outcomes of Adults in Substance Abuse Treatment centers with Possible or Probable Schizophrenia

Kimberlee J. Trudeau, Joanna Burtner, Kruti Joshi, Albert Villapiano, Megan Jones, & Stephen F. Butler Presented at ARM 2016 See our poster for “A Cross-Sectional Analysis of Economic, Medical, and Legal Outcomes of Adults in Substance Abuse Treatment centers with Possible or Probable Schizophrenia” here Research Objective:  In the fragmented US healthcare system, patients seeking substance abuse… Read more »

ER vs. IR Drugs: An Interview with Theresa Cassidy, VP of Health Analytics

Inflexxion’s Vice President of Health Analytics, Theresa Cassidy, was recently interviewed on the issues and abuse of Extended Release (ER) opioids vs. Immediate Release (IR) opioids based on supporting data and analytics. Q1: Extended Release opioids have more stringent regulatory restrictions because of their potential for tampering/abuse. The focus on extended-release/long acting opioids as a class… Read more »

Recent Study: Progression of non-medical use of hydrocodone combination products: results from an Internet survey of recreational drug users

Earlier this year, Inflexxion and KemPharm Pharmaceuticals presented a poster at the International Conference on Opioids based on a recent study of non-medical use of prescription opioids.  According to SAMSHA, Non-medical use of prescription opioids continues to increase.  However, little is known about the potential impact commonly prescribed opioids, such as hydrocodone combination products (HCPs), have… Read more »

Inflexxion to provide data to FDA to evaluate opioid-related drug risks

Inflexxion, Inc. Awarded FDA Contract to Assist in Evaluation of Opioid-Related Drug Risks Inflexxion to provide analysis to the FDA from its surveillance data system on prescription drug abuse NEWTON, MA (October 17, 2016) – The US Food and Drug Administration (FDA) has awarded Inflexxion, Inc. a five-year, $10 million IDIQ contract.  The contract addresses,… Read more »

New Infographic! Online Assessment Equals Better Data

  Inflexxion recently concluded a study of the standardized electronic pain assessment system, the PainCAS: Clinical Assessment System.  The study measured the system’s impact on pain-related documentation.  Below is an infographic that highlights the key findings from the study.  

Behavioral Health Solutions Subscription Plan

    Did you know that using an electronic intake assessment tool instead of paper increases efficiencies and results in better patient communication?  If you’re considering ways to improve your clinical setting, it’s time to consider a behavioral health assessment solution. Inflexxion’s new subscription-based plan for our behavioral health product suite, including the ASI-MV, BHI-MV,… Read more »

Aspire Health Partners BHI-MV Case Study

Aspire Health Partners improves assessment, recovery and outcomes while reducing costs with online behavioral health tool the BHI-MV.   Being the state’s largest provider of behavioral health services requires Aspire Health Partners to balance providing clients with the highest quality of care while implementing cost saving measures. For 10 years, Aspire Health Partners has been… Read more »

Interview with Dr. Simon Budman, Founder & Chief Strategy Officer at Inflexxion

  We recently spoke with Dr. Simon Budman, an internationally known researcher and innovator, on his thoughts about the challenges around opioid abuse including the significance of routes of administration and the role of generics in the marketplace. Q1: Dr. Budman, what’s the significance of abusers using alternative routes of administration? A: It’s essential to… Read more »

FDA releases steps to ensure safety of abuse-deterrent generic opioids

On March 24, 2016 the Food and Drug Administration (FDA) announced draft guidance for generic versions of approved abuse deterrent formulations (ADF).  The guidance, which is focused on creating policies to address the opioid epidemic, comes out of the action plan that the FDA created in April, 2015 to begin reevaluating the approach to prescription… Read more »